Based on the KEGG pathway enrichment analysis results, we can see that the QSDH drug formulary exerts its effect on the treatment of MG mainly through signaling pathways such as the IL-17 signaling pathway, the HIF-1 signaling pathway, the PI3K-AKT signaling pathway, and the mTOR signaling pathway. Here, AKT1 is linked to myasthenia gravis.